- Home
- MGNX vs UEIC Comparison
MGNX vs UEIC Comparison
Compare MGNX & UEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- UEIC
- Stock Information
- Founded
- MGNX 2000
- UEIC 1986
- Country
- MGNX United States
- UEIC United States
- Employees
- MGNX N/A
- UEIC N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- UEIC Consumer Electronics/Appliances
- Sector
- MGNX Health Care
- UEIC Consumer Staples
- Exchange
- MGNX Nasdaq
- UEIC Nasdaq
- Market Cap
- MGNX 87.7M
- UEIC 88.0M
- IPO Year
- MGNX 2013
- UEIC 1993
- Fundamental
- Price
- MGNX $1.61
- UEIC $6.83
- Analyst Decision
- MGNX Hold
- UEIC Strong Buy
- Analyst Count
- MGNX 9
- UEIC 2
- Target Price
- MGNX $5.33
- UEIC $14.50
- AVG Volume (30 Days)
- MGNX 1.3M
- UEIC 29.3K
- Earning Date
- MGNX 08-05-2025
- UEIC 08-07-2025
- Dividend Yield
- MGNX N/A
- UEIC N/A
- EPS Growth
- MGNX N/A
- UEIC N/A
- EPS
- MGNX N/A
- UEIC N/A
- Revenue
- MGNX $154,050,000.00
- UEIC $395,305,000.00
- Revenue This Year
- MGNX N/A
- UEIC $3.89
- Revenue Next Year
- MGNX N/A
- UEIC $4.35
- P/E Ratio
- MGNX N/A
- UEIC N/A
- Revenue Growth
- MGNX 255.31
- UEIC N/A
- 52 Week Low
- MGNX $0.99
- UEIC $4.32
- 52 Week High
- MGNX $5.77
- UEIC $12.64
- Technical
- Relative Strength Index (RSI)
- MGNX 59.02
- UEIC 50.84
- Support Level
- MGNX $1.34
- UEIC $6.73
- Resistance Level
- MGNX $1.65
- UEIC $7.29
- Average True Range (ATR)
- MGNX 0.11
- UEIC 0.39
- MACD
- MGNX 0.04
- UEIC 0.01
- Stochastic Oscillator
- MGNX 91.40
- UEIC 63.78
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.